Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Bluebird bio orchestrates a series of deals and a buyout to guarantee gene therapy manufacturing

8 years ago

You want to charge $1M for that gene therapy? Here’s where you’re wrong

8 years ago

How much is your vision worth? Spark CEO Jeff Marrazzo has a price in mind

8 years ago

AveXis offers compelling reasons for a fast FDA OK for gene therapy to treat spinal muscular atrophy in infants

8 years ago

#ASH17: Bluebird touts early signs that its new-and-improved sickle cell gene therapy is working

8 years ago

Sanofi Genzyme retreats from its Parkinson’s deal with gene therapy upstart Voyager, part of an $845M pact

8 years ago

With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy

8 years ago

In a PhIII showdown with Spark, uniQure switches out its lead gene therapy for hemophilia B

8 years ago

Armed with $42.5M, Gemini embraces the Goldilocks strategy in bringing precision med to AMD

8 years ago

FDA experts offer a unanimous endorsement for Spark’s pioneering AAV gene therapy for blindness

8 years ago

Spark Therapeutics faces a grilling as FDA ponders a pioneering OK for gene therapy

8 years ago

Bluebird’s gene therapy shows promise in keeping lethal Lorenzo’s Oil disease in check

8 years ago

Voyager Therapeutics adds proof its gene therapy for Parkinson's can work, shares soar

8 years ago

Big names, big companies back a cell therapy startup run by a high-profile regenerative med expert

8 years ago

Orbimed partner in search of a cure for Parkinson’s launches new gene therapy player

8 years ago

Spark Therapeutics offers a glimpse of efficacy in first two hemophilia A gene therapy patients

8 years ago

FDA embraces the first US application for a gene therapy, offering an accelerated test case

8 years ago

Pioneering gene therapy patients stay on track, boosting Spark’s hemophilia B program

8 years ago

Bluebird bio steps up with a promising snapshot of its gene therapy upgrade

8 years ago

Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal

9 years ago

Spark carefully records a safe step forward for closely-watched hemophilia gene therapy

9 years ago

Solid Biosciences appears to be prepping for an IPO with $50M round for Duchenne gene therapy

9 years ago

A gene therapy pioneer moves from Biogen to Regenxbio, staying focused on gene therapy 2.0

9 years ago

Months after another lethal setback, Juno finally opts to kill lead CAR-T

9 years ago

First page Previous page 55 56 575859 Next page Last page